Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results-Reference-Cited by-同舟云学术

Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results

Published:2021-10-01 Issue:10 Volume:37 Page:761-767
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Arancón Pardo Ana¹^ORCID,Moreno Palomino Marta¹,Jiménez-Nácher Inmaculada¹,Moreno Francisco¹,González Fernández María Ángeles¹,González-García Juan²,Herrero Ambrosio Alicia¹

Affiliation:

1. Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain.

2. Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital-IdiPAZ, Madrid, Spain.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2021.0041

Reference21 articles.

1. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

2. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

3. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study;AIDS Research and Human Retroviruses;2024-01-05

2. Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa;Pediatric Infectious Disease Journal;2023-02-14

3. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature;Expert Review of Anti-infective Therapy;2022-11-27

4. Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea;Viruses;2022-11-18